Page 6 - Diagnostics Division News Today

Basel, 3 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Matt Sause (45), currently Head of Roche Diagnostics' North America Region, will become CEO Roche Diagnostics and a member

The FINANCIAL -- Commenting on the Group’s first nine months, Roche CEO Severin Schwan said: “We had continued good sales growth in both Pharmaceuticals and Diagnostics driven by our newly launched products, and our product pipeline is developing very well. Our cancer immunotherapy medicine Tecentriq has been performing strongly since May, when it was first approved in the US for people with advanced bladder cancer, and it has just received US FDA approval for previously treated metastatic n...

Christoph Franz has decided not to seek re-election to the Board of Directors at the Annual General Meeting (AGM) in March 2023 The Board of Directors intends to propose Severin Schwan as new Chairman

Basel, 21 July 2022 Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Division sales increase 3%; continued strong demand for new medicines to treat severe

Roche's (RHHBY) (RHHBF) Diagnostics division head will take over as Group CEO, replacing incumbent Severin Schwan, effective March 15, 2023.The Swiss company's board intends to...

Christoph Franz has decided not to seek re-election to the Board of Directors at the Annual General Meeting (AGM) in March 2023 The Board of Directors...

The upcoming leadership changes were unveiled as Roche released its financial results from the first half of 2022.

Investegate announcements from Avacta Group PLC, Result of Annual General Meeting

Declining demand for COVID-19 screening tests calls for a new focus.

Press release content from Business Wire. The AP news staff was not involved in its creation.